ZVRA ZEVRA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1434647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY75.1%
TTM net income YoY120.8%
TTM EPS YoY159.6%
Revenue 3-yr CAGR106.2%
Net income 3-yr CAGR—
Margins
Gross margin95.4%
Operating margin60.8%
Net margin52.8%
FCF margin25.9%
EBITDA margin61.8%
Returns
ROE41.9%
ROA26.7%
ROIC (approx.)60.6%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio5.46x
Interest coverage24.55x
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio13.5%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $106.47M | $23.61M |
| Cost of revenue | $16.48M | $7.42M |
| Gross profit | $89.99M | $16.20M |
| R&D expense | $12.74M | $42.09M |
| SG&A expense | $77.62M | $54.87M |
| Operating income | -$62.94M | -$87.00M |
| Interest expense | $7.98M | $7.35M |
| Pretax income | $86.68M | -$90.14M |
| Income tax | $3.45M | $15.37M |
| Net income | $83.23M | -$105.51M |
| EBITDA | -$58.89M | -$80.61M |
| EPS (basic) | 1.40 | -2.28 |
| EPS (diluted) | 1.35 | -2.28 |
| Weighted avg. shares (diluted) | 57.26M | 46.25M |
| Balance sheet | ||
| Cash & equivalents | $62.41M | $33.78M |
| Short-term investments | $128.60M | $35.71M |
| Receivables | — | $10.18M |
| Inventory | $1.74M | $1.97M |
| Current assets | $223.01M | $86.03M |
| PP&E, net | $489,000 | $356,000 |
| Goodwill | $4.70M | $4.70M |
| Intangibles | $6.42M | $68.99M |
| Total assets | $284.73M | $178.13M |
| Current liabilities | $39.28M | $34.06M |
| Long-term debt | $61.93M | $59.50M |
| Total debt | $61.93M | $59.50M |
| Total liabilities | $130.07M | $138.46M |
| Shareholders' equity | $154.66M | $39.67M |
| Net debt | -$478,000 | $25.72M |
| Shares outstanding | 56.85M | 53.67M |
| Cash flow statement | ||
| Operating cash flow | -$1.60M | -$69.67M |
| Capital expenditure | $835,000 | $0 |
| Free cash flow | -$2.43M | -$69.67M |
| Investing cash flow | $18.13M | -$22.16M |
| Financing cash flow | $12.06M | $82.11M |
| Depreciation & amortization | $4.05M | $6.39M |
| Stock-based compensation | $12.63M | $14.91M |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.